Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant ...

Celcuity said its Phase 3 clinical trial evaluating gedatolisib resulted in positive topline results. The clinical-stage biotechnology company's trial evaluated gedatolisib plus fulvestrant with and ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

Celcuity Inc. (NASDAQ:CELC) saw its stock soar by more than 100% on Monday following the release of groundbreaking Phase 3 ...

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are ...

The addition of dalpiciclib to fulvestrant appeared effective and safe for certain patients with advanced breast cancer, according to randomized phase 3 study results presented during the virtual ...

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...

For fulvestrant to work well, the cells must also be responsive to estrogen, and producing the estrogen receptor ER-alpha. ER-alpha's importance to fulvestrant's anti-estrogenic action had been ...